Prognosis
AstraZeneca Resumes Vaccine Trial in Japan; U.S. Still on Hold
- Trials were paused globally after volunteer became sick
- U.S. studies remain on hold as regulators assess event
This article is for subscribers only.
A vaccine trial for a front-runner Covid-19 shot from AstraZeneca Plc and the University of Oxford restarted in Japan after studies were halted globally last month when a U.K. participant became ill.
The phase I-II trials resumed after the Japanese regulator gave the go-ahead, according to a statement from AstraZeneca Friday. Studies in the U.K., Brazil, South Africa and India have also restarted in recent weeks.